Introduction to Work Pattern and Experience of American Research on Adverse Drug Events and Reports SUN Zhong-shi

Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (2): 109-111.

Introduction to Work Pattern and Experience of American Research on Adverse Drug Events and Reports SUN Zhong-shi

Received:2014-02-13 Revised:2016-02-03 Online:2014-02-08 Published:2016-02-03

Abstract

Abstract: Objective To summarize the experience of American Research on Adverse Drug Events and Reports(RADAR), so as to provide reference to pharmacovigilance in China. Methods Through collecting literatures, the achievements of RADAR were summarized, and its work pattern was analyzed. Results and Conclusion Based on clinic, RADAR can make prospective evaluation on cases of adverse drug reactions and discover new adverse drug reactions more quickly.

Key words: pharmacovigilance, RADAR, work pattern, experience

CLC Number:

R994.11

[1]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[2]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[3]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[4]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[5]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[8]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[9]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[10]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[11]	PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
[12]	JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
[13]	WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong. Current applications of artificial intelligence in pharmacovigilance in the USA and implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
[14]	ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia. Thyroid immune-related adverse reactions of immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
[15]	JIANG Hao, ZHANG Bing, ZHANG Xiaomeng, LIN Zhijian, LYU Jintao, ZHANG Dan. Descriptions of pharmacovigilance in materia medica works of Sui, Tang and the Five Dynasties [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 987-993.

Introduction to Work Pattern and Experience of American Research on Adverse Drug Events and Reports SUN Zhong-shi

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics